Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

28 results about "Edetic Acid" patented technology

A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.

Pantoprazole sodium for injection and preparation method thereof

The invention provides pantoprazole sodium for injection, which is prepared by dissolving 40 parts of pantoprazole sodium, 25 parts of amino-PEG-mannose, 0.5 part of disodium calcium ethylene diamine tetraacetate and water for injection to 1000 parts and freeze-drying, the redissolution time of pantoprazole sodium for injection is short, related substances in the solution are not increased, the content is not obviously reduced, and the pantoprazole sodium for injection is suitable for clinical application. The stability is good in the transportation and storage process, the compatible solution can be stored for a long time during clinical use, clinical use becomes more convenient, and the problems of medication potential safety hazards, side effects and the like brought to patients due to impurity increase, content reduction and the like are also greatly reduced.
Owner:NANJING YISHU PHARMACEUTICAL INFORMATION TECHNOLOGY CO LTD

Nutrition regulating agent for regulating mature period of citrus fruits and application of nutrition regulating agent

The invention discloses a nutrition regulating agent for regulating the mature period of citrus fruits and application of the nutrition regulating agent. The nutrition regulating agent is prepared from potassium nitrate, monopotassium phosphate, magnesium sulfate, ferric sodium ethylenediaminetetraacetate, zinc sodium ethylenediaminetetraacetate, boric acid, ammonium molybdate, gibberellin, abscisic acid and diatomite which is supplemented to 100 parts. The invention further provides a preparation method of the nutrition regulating agent and application of the nutrition regulating agent in regulating the mature period of citrus fruits, and the application mode is that when the diameter of the citrus fruits is 40-50 mm, the preparation is diluted by 600-800 times to be sprayed on leaf surfaces, once every 7 days and twice continuously. Through the synergistic effect of mineral nutrient elements and low-concentration hormones, bidirectional precise regulation and control of the citrus mature period are achieved, fruits can be promoted to mature in advance or later for 7-15 days, the sugar-acid ratio and color of the fruits can be remarkably improved, meanwhile, the problems of tree vigor decline and quality decline caused by single hormone treatment are solved, and the method is suitable for large-scale popularization and application. The method has the characteristics of high efficiency, safety and simple operation.
Owner:HUANING TIANMING ECONOMIC & TRADE CO LTD

Wound contact layer with infection-inhibiting properties

PendingUS20250281663A1Absorbent padsDressingsAntimicrobial actionEdetic Acid
The present invention relates to a wound contact layer which is suitable for wound care. The wound contact layer comprises a mesh-like substrate which is partially or completely coated with an emulsion, wherein the emulsion comprises an antimicrobial composition containing a) ionic silver and / or silver nitrate, b) ionic zinc and / or zinc nitrate, and c) EDTA. The wound contact layer has an antimicrobial effect and is effective against biofilms. The wound contact layer enables wound care and promotes wound healing.
Owner:PAUL HARTMANN AG

Production process of diphenhydramine hydrochloride injection

The invention discloses a production process of a diphenhydramine hydrochloride injection, and relates to the technical field of nano modification. A citric acid-sodium citrate (or sodium hydroxide) pH buffer pair is added into a prescription, the pH of liquid medicine is controlled within the range of 6.0-6.5, meanwhile, sterilization is conducted through an excessive killing method at the temperature of 121 DEG C for 15 min, and efficient sterile guarantee is achieved. In order to inhibit the generation of impurities under the catalysis of metal ions at a high temperature, an edetic acid complexing agent is introduced into the process, and a scheme of EDTA modification or combined complexing with non-toxic auxiliary materials is discussed. A multi-batch accelerated stability test result shows that each quality index of the product prepared by the process meets USP and related standard requirements, the stability and the sterile level of the injection are effectively improved, and the feasibility of commercial production is achieved.
Owner:SHANGHAI ZHAOHUI PHARMA

Novel oral care formulations for treatment of xerostomia

A formulation for treating xerostomia and alleviating the symptoms of dry mouth is provided. Formulations comprising a humectant (such as propylene glycol), a chelator (such as EDTA and its salts) and a transport enhancer (such as methylsulfonylmethane (MSM)) are provided.
Owner:LIVIONEX INC

Thyroid nodule puncture sample DNA and RNA extraction method and kit

PendingCN121780512Areduce dosageAddressing sample size limitationsDNA preparationEdetic AcidRadiology
The invention discloses a thyroid nodule puncture sample DNA and RNA extraction method and a kit, and relates to the technical field of biology. The kit comprises a lysis solution and a nucleic acid protective agent, the lysate is prepared from guanidine hydrochloride, guanidine isothiocyanate, sodium citrate, lauryl sodium sulfate, ethylenediamine tetraacetic acid, Nonet P-40, polyvinylpyrrolidone, Triton X-100 and tris (hydroxymethyl) aminomethane; the nucleic acid protective agent is composed of dithiothreitol and tris (2-carboxyethyl) phosphine. According to the kit provided by the invention, the extraction efficiency is improved, and the flexibility of sample treatment is improved by optimizing the components of the lysis solution, increasing the lysis efficiency of different tissue quantities, jointly using the nucleic acid protective agent and inhibiting the nuclease activity in a sample, so that the individual detection requirements of more patients can be met. Through the application of the nucleic acid protective agent, the operation steps are simplified, and the safety is enhanced.
Owner:BEIJING SINOMDGENE TECH CO LTD +1

Ionic liquid chain transfer agent as well treatment additive

ActiveUS12398313B2Fluid removalDrilling compositionEdetic AcidMedicine
Well treatment fluids comprise well treatment additives comprising an ionic liquid. Method of treating a subterranean formation may comprise contacting the subterranean formation with the well treatment additive, wherein the well treatment additive comprises an ionic liquid comprising a cation and an anion having the following formula: [R1R2R3R4N]+[X]−, wherein R1, R2, R3, R4 are individually selected from the group consisting of an alkyl group, a hydroxyalkyl group, and a combination thereof provided that at least one of R1, R2, R3, R4 is the hydroxyalkyl group, and wherein the anion X− comprises at least one anion selected from the group consisting of F−, Cl−, Br−, I−, H2PO4−, HPO42−, PO43−, HSO4−, C7H7OSO3−, C7H7SO3−, SO42−, CH3SO3−, C2H5SO3−, CH3OSO3−, C2H5OSO3−, and combinations thereof.
Owner:HALLIBURTON ENERGY SERVICES INC

Multi-effect home care solution containing compound enzyme and essential oil as well as preparation method and application of multi-effect home care solution

The invention discloses a multi-effect home care solution containing a compound enzyme and essential oil and a preparation method of the multi-effect home care solution. The multi-effect home care solution is prepared from the following raw materials: the compound enzyme, vitamin E, the essential oil, PEG-40 hydrogenated castor oil, polyhexamethylene biguanide hydrochloride, alkyl glucoside, 1, 3-butanediol, glycerol, urea, phenoxyethanol, ethylenediamine tetraacetic acid disodium salt and deionized water. The essential oil is at least one of cedar essential oil, tea tree essential oil and chamomile essential oil. The preparation method comprises the following steps: mixing and heating essential oil and PEG-40 hydrogenated castor oil to prepare an essential oil microemulsion, adding vitamin E, 1, 3-butanediol and phenoxyethanol into the essential oil microemulsion, homogenizing to obtain a uniform oil phase, mixing and heating other raw materials to prepare a uniform water phase, adding the uniform oil phase into the uniform water phase to prepare an oil-in-water microemulsion, and uniformly stirring to prepare the oil-in-water microemulsion. And finally, adjusting the pH value by using citric acid. The multi-effect home care solution can be used for cleaning, nourishing, bacteriostasis, aging resistance and formaldehyde removal of leather, synthetic leather products and wooden furniture products, and is free of solvent residues.
Owner:HENAN SURANYIJIA BIOLOGICAL ENGINEERING CO LTD

A maropitant citrate injection and a method of preparing the same

PendingCN122272501AEdetic AcidBioavailability
This invention discloses a maripitan citrate injection and its preparation method, relating to the field of pharmaceutical formulation technology. It addresses the technical problems of existing maripitan citrate injections, such as low bioavailability, poor stability, and susceptibility to adverse reactions during injection. The maripitan citrate injection comprises maripitan citrate, TPGS-SO3H, zinc sodium EDTA, and water for injection. The mass ratio of maripitan citrate (calculated as maripitan) to TPGS-SO3H is 1:(1-2), and the mass ratio of TPGS-SO3H to zinc sodium EDTA is (100-200):(1-2). The maripitan citrate injection provided by this invention can effectively improve the bioavailability and stability of the product, while reducing adverse reactions such as injection pain.
Owner:SICHUAN KANGQUAN BIOTECHNOLOGY CO LTD

A crystallization process for p-aminosalicylic acid

The present invention relates to the field of pharmaceutical chemistry technology, specifically, to a crystallization process for p-aminosalicylic acid. It comprises the following steps: p-aminosalicylic acid crude product is dissolved in a solvent, disodium edetate is added synchronously to form a homogeneous solution; polyvinyl pyrrolidone and sodium lauryl sulfate are dissolved in water to form a composite micelle system, and acetone is added to form an anti-solvent phase; the anti-solvent phase is added dropwise to the homogeneous solution, and target crystal form seed is injected; the solution is subjected to solid-liquid two-phase separation; solid phase is treated to obtain wet crystals; wet crystals are processed by a vacuum belt dryer to obtain p-aminosalicylic acid crystals. In the present invention, metal-catalyzed decarboxylation is blocked by disodium edetate, free impurities are adsorbed with polyvinyl pyrrolidone-sodium lauryl sulfate micelles, and polyvinyl pyrrolidone can stabilize the target crystal lattice, and sodium lauryl sulfate can induce crystal growth, so as to stably output low residual high-purity pharmaceutical-grade p-aminosalicylic acid.
Owner:LIAOYUAN SILVER EAGLE PHARM CO LTD

African swine fever virus sample protection liquid and preparation method thereof

The invention relates to the technical field of biology. The invention provides an African swine fever virus sample protection solution, which is characterized by comprising the following components in percentage by weight: 15 to 35 percent of guanidine isothiocyanate, 0.4 to 2.0 percent of sodium dodecyl sarcosinate, 0.8 to 3.0 percent of Ectoine, 0.1 to 0.5 percent of tris (2-carboxyethyl) phosphine hydrochloride, 0.2 to 0.8 percent of disodium ethylene diamine tetraacetate, 0.4 to 1.5 percent of sodium citrate and the balance of Tris-HCl buffer solution. The protection liquid can thoroughly inactivate viruses to guarantee safety, can resist high temperature, and effectively solves the problem of preservation of African swine fever samples at high temperature; meanwhile, the detection sensitivity of a sample treated by the protection liquid is better, and the accuracy is higher.
Owner:LIAOCHENG UNIV

Pharmaceutical composition containing pyridylaminoacetic acid compound

The purpose of the present invention is to provide a pharmaceutical composition that comprises a specific compound and exhibits a superior preservation efficacy, the specific compound being stable within the pharmaceutical composition, and to provide methods for improving the stability of the specific compound within the pharmaceutical composition and the preservation efficacy of the pharmaceutical composition. The pharmaceutical composition according to the present invention comprises isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and further comprises edetic acid or a salt thereof.
Owner:SANTEN PHARMACEUTICAL CO LTD

Paraben-free fexofenadine formulation

PendingJP2026501487ASenses disorderDispersion deliveryBenzoic acidFexofenadine
Fexofenadine zwitterionic dihydrate form I of formula (I) Paraben-free aqueous pharmaceutical suspension formulations and uses thereof are provided, including JPEG2026501487000031.jpg4390. In certain embodiments, the formulations include polypropylene glycol, edetate disodium, potassium sorbate, xanthan gum, poloxamer 407, titanium dioxide, sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate, artificial raspberry cream flavor, sucrose, xylitol, and purified water. The disclosure also includes methods of making such formulations.
Owner:オペラ ヘルスケア グループ ソシエテ パル アクシオン サンプリフィエ

Hair growth or hair care agent composition

To provide a hair growth or hair care agent composition containing hinokitiol, salicylic acid, edetic acid salt, and ethanol, which does not produce precipitates over time.SOLUTION: The above problems are solved by a hair growth or hair care agent composition containing at least hinokitiol, salicylic acid, edetic acid salt, and ethanol, a content of the edetic acid salt being 0.02 mass / volume% or more relative to the total volume of the composition, and a content of the ethanol being 30 to 70 vol.%, and pH is 3.7 or more and less than 6.0.SELECTED DRAWING: None
Owner:DAIICHI SANKYO HEALTHCARE

A bath foam based on high-purity artemisia extract and a preparation method thereof

This application belongs to the field of daily chemical product preparation technology, specifically providing a shower gel based on high-purity Artemisia argyi extract and its preparation method, including deionized water, disodium EDTA, dodecyl alcohol polyoxyethylene ether sulfate, cocamidopropyl betaine, PEG-80 sorbitan laurate, glycerin, DOE-120 thickener, Artemisia argyi high-purity extract nanoemulsion, and phenoxyethanol. The shower gel based on high-purity Artemisia argyi extract prepared by this application can stably disperse high-purity Artemisia argyi extract and other functional essential oils in the form of a nanoemulsion, improving the stability and efficacy of the essential oil components. The resulting product has the advantages of good stability, pleasant skin feel, long-lasting fragrance, and both cleansing and soothing effects.
Owner:LEAI TECHNOLOGY (HUBEI) CO LTD

A combination of calcium, iron, zinc, and multivitamins containing NFC lemon juice to synergistically promote absorption and aid growth.

This invention belongs to the field of food technology and discloses a calcium, iron, zinc, and complex vitamin synergistic absorption-promoting and growth-aiding composition containing NFC lemon juice. The composition uses NFC lemon juice as the basic functional carrier and is compounded with specific organic minerals L-calcium lactate, zinc lactate, sodium ferric EDTA, and water-soluble vitamins (vitamin C and various B vitamins) to construct a synergistic absorption nutritional system. Through formula optimization and process innovation, this invention effectively improves the chelation rate of minerals, reduces the risk of product precipitation to ensure stability, achieves a synergistic absorption-promoting effect of minerals and vitamins, supports growth and development, and is suitable for industrial production needs.
Owner:WUHAN NATURAL EXTRACTION INNOVATION TECH CO LTD

Paraben-free fexofenadine formulations

Provided is a paraben-free aqueous pharmaceutical suspension formulation comprising fexofenadine zwitterionic dihydrate Form I of formula (I)and uses thereof. In certain embodiments, the formulation comprises polypropylene glycol, edetate disodium, potassium sorbate, xanthan gum, poloxamer 407, titanium dioxide, sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate, artificial raspberry cream flavor, sucrose, xylitol, and purified water. The disclosure also includes methods of making such formulations.
Owner:OPELLA HEALTHCARE GRP SAS

Wound contact layer with anti-infective properties

The present invention relates to a wound contact layer suitable for wound care. The wound contact layer comprises a mesh-like substrate partially or completely coated with an emulsion, wherein the emulsion comprises an antimicrobial composition containing a) ionic silver and / or silver nitrate, b) ionic zinc and / or zinc nitrate, and c) EDTA. The wound contact layer exerts an antimicrobial effect and is effective against biofilms. The wound contact layer enables wound care and promotes wound healing.
Owner:PAUL HARTMANN AG

Compositions containing rapid-acting insulin analogues

A pharmaceutical composition comprises an effective amount of an insulin analogue comprising modified A-chain and B-chain polypeptides. The modified A chain comprises one or more substitutions relative to wild-type human insulin A-chain selected from a Gln, His or Glu substitution at position A8, a Glu or Ala substitution at position A14, and an Ala, Gln, Gly, or Thr substitution at position A21. The modified B-chain polypeptide comprises one or more modifications relative to wild-type human insulin B-chain selected from a deletion of the amino acid or amino acids at position B1, B1 and B2, or B1-B3, an Ala or Glu substitution at position B2, a Glu or Ala substitution at position B3, an Ala substitution at position B4; and a Glu or Lys substitution at position B29. The composition comprises one or more of iloprost, citrate, EDTA and a polyphosphate compound. The composition may be used to treat diabetes.
Owner:INVICTUS THERAPEUTICS LLC

External-use composition

A composition for external use comprising (A) an ascorbic acid compound, derivatives and salts thereof; (B) an edetic acid salt; (C) a glycyrrhizic acid salt; (D) a heparinoid; and (E) water and an ascorbic acid compound-containing composition for external use in which precipitation under low-temperature storage conditions is suppressed.
Owner:KOBAYASHI PHARMA CO LTD

Gynecological antibacterial gel and preparation method thereof

The invention discloses gynecological antibacterial gel and a preparation method thereof, relates to the technical field of biological medicine manufacturing, and belongs to the patent classification number A61K38 / 47. The preparation method comprises the following steps: mixing the methylparaben, the propylparaben and the propylene glycol, heating and stirring until the methylparaben, the propylparaben and the propylene glycol are completely dissolved to obtain a component B; carbomer is added into deionized water and stirred to be dissolved, then lysozyme slow-release composite microspheres are added and continuously stirred to be dispersed uniformly, then cocamidopropyl betaine, coco-glucoside, lauryl glucoside, poloxamer, glycerin, disodium ethylene diamine tetraacetate and triethanolamine are added and heated, stirred and dissolved uniformly, and a component A is obtained; and adding the component B into the component A, and uniformly stirring and mixing to obtain the gynecological antibacterial gel. According to the invention, the release speed of the lysozyme in the gynecological antibacterial gel can be delayed, so that the antibacterial performance can be stably exerted for a long time.
Owner:YANCHENG QIUHENG MEDICAL DEVICES

Pharmaceutical formulation with improved stability comprising endoglycosidase hydrolase

PCT designated stageWO2026141833A1Sodium acetateEdetic Acid
The present invention relates to a pharmaceutical formulation with improved stability, comprising: an endoglycosidase hydrolase; a phosphate-based buffer; a stabilizer comprising sodium chloride, sodium edetate, and calcium chloride; and a nonionic surfactant.
Owner:HUONSLAB CO LTD

Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol

The present disclosure provides aqueous formulations comprising hydrocortisone sodium phosphate and monothioglycerol. In some embodiments, the formulations comprise monobasic sodium phosphate, dibasic sodium phosphate, or disodium EDTA. The present disclosure further provides a method of treating a disease or disorder in a subject by administering the aqueous formulation.
Owner:ANTARES PHARMA INC

Aqueous liquid formulation

PendingJP2026020360AOrganic active ingredientsSenses disorderEdetic AcidPreservative free
An object of the present invention is to provide a preparation technique for providing an aqueous liquid preparation containing brimonidine and / or a salt thereof with preservative efficacy of at least a level at which a bacteriostatic action is recognized, without blending a preservative.SOLUTION: An aqueous liquid preparation containing brimonidine and / or a salt thereof, edetic acid and / or a salt thereof, and a buffering agent can have preservative efficacy at a level at which at least a bacteriostatic action is observed, even if it does not substantially contain a preservative.SELECTED DRAWING: None
Owner:SENJU PHARMA CO LTD

Transparency pretreatment

The present invention addresses the problem of providing a transparency pretreatment composition for use in transparency methods for biological specimens, as well as a biological specimen transparency method and transparency kit containing said composition. According to the present invention, there is provided a transparency pretreatment composition for biological specimens, said composition being (A) an aqueous solution containing an alkali metal carbonate or bicarbonate and hydrogen peroxide, (B) an aqueous solution containing ammonia and hydrogen peroxide, or (C) an aqueous solution containing an alkali metal salt of EDTA and hydrogen peroxide. According to the present invention, there is provided a biological specimen transparency method comprising a step (1) for treating an object to be made transparent, i.e., a biological specimen, with the transparency pretreatment composition for biological specimens and a step (2) for treating the object to be made transparent, which has been treated with the transparency pretreatment composition for biological specimens in step (1), with a transparency solution to obtain said object made transparent. Also provided is a transparent biological specimen preparation kit containing the transparency pretreatment composition for biological specimens and the transparency solution.
Owner:KANAZAWA MEDICAL UNIVERSITY

Paraben-free fexofenadine formulations

Provided is a paraben-free aqueous pharmaceutical suspension formulation comprising fexofenadine zwitterionic dihydrate Form I of formula (I) and uses thereof. In certain embodiments, the formulation comprises polypropylene glycol, edetate disodium, potassium sorbate, xanthan gum, poloxamer 407, titanium dioxide, sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate, artificial raspberry cream flavor, sucrose, xylitol, and purified water. The disclosure also includes methods of making such formulations.
Owner:OPELLA HEALTHCARE GRP SAS